Calidi Biotherapeutics, Inc. earnings per share and revenue
On Nov 13, 2025, CLDI reported earnings of -2.21 USD per share (EPS) for Q3 25, missing the estimate of -1.71 USD, resulting in a -28.97% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a +0.66% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
FAQ
What were Calidi Biotherapeutics, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Calidi Biotherapeutics, Inc. reported EPS of -$2.21, missing estimates by -28.97%, and revenue of --, -- -- expectations.
How did the market react to Calidi Biotherapeutics, Inc.'s Q3 2025 earnings?
The stock price moved up 0.66%, changed from $1.51 before the earnings release to $1.52 the day after.
When is Calidi Biotherapeutics, Inc. expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Calidi Biotherapeutics, Inc.'s next earnings report?
Based on --
analysts, Calidi Biotherapeutics, Inc. is expected to report EPS of -- and revenue of -- for Q-- --.